Atul Dandekar Sells 7,500 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the sale, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. This represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total transaction of $210,150.00.

Maze Therapeutics Stock Performance

Maze Therapeutics stock traded down $0.71 during trading hours on Friday, reaching $26.92. 335,578 shares of the stock were exchanged, compared to its average volume of 682,907. The stock has a market cap of $1.49 billion, a P/E ratio of -10.64 and a beta of 2.14. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. Maze Therapeutics, Inc. has a 52-week low of $12.81 and a 52-week high of $53.65. The firm’s 50 day moving average is $27.34 and its 200 day moving average is $34.10.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Analysts predict that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics in the fourth quarter valued at $39,000. Ameritas Investment Partners Inc. increased its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics during the fourth quarter worth about $43,000. Finally, Russell Investments Group Ltd. lifted its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MAZE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Truist Financial reduced their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.